Bruce & Co’s Fate Therapeutics FATE Stock Holding History

Bruce & Co’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.67M	Buy	989,188 +200,000	+25%	+$370K	0.72%	28
2026 Q1	$947K	Buy	789,188 +60,000	+8%	+$73K	0.27%	34
2025 Q4	$717K	Hold	729,188	–	–	0.22%	35
2025 Q3	$919K	Buy	729,188 +300,000	+70%	+$323K	0.28%	34
2025 Q2	$481K	Sell	429,188 -120,812	-22%	-$140K	0.16%	39
2025 Q1	$435K	Buy	550,000 +200,000	+57%	+$245K	0.14%	38
2024 Q4	$578K	Hold	350,000	–	–	0.19%	36
2024 Q3	$1.23M	Buy	350,000 +50,000	+17%	+$195K	0.36%	32
2024 Q2	$984K	Buy	300,000 +157,000	+110%	+$687K	0.32%	32
2024 Q1	$1.05M	Hold	143,000	–	–	0.35%	30
2023 Q4	$535K	Sell	143,000 -57,000	-29%	-$135K	0.19%	34
2023 Q3	$424K	Hold	200,000	–	–	0.14%	35
2023 Q2	$956K	Hold	200,000	–	–	0.27%	28
2023 Q1	$1.14M	Buy	200,000 +143,000	+251%	+$863K	0.31%	27
2022 Q4	$575K	Hold	57,000	–	–	0.15%	32
2022 Q3	$1.28M	Hold	57,000	–	–	0.35%	27
2022 Q2	$1.41M	Hold	57,000	–	–	0.33%	27
2022 Q1	$2.21M	Hold	57,000	–	–	0.45%	25
2021 Q4	$3.33M	Hold	57,000	–	–	0.67%	23
2021 Q3	$3.38M	Sell	57,000 -5,000	-8%	-$392K	0.72%	24
2021 Q2	$5.38M	Sell	62,000 -3,000	-5%	-$242K	1.03%	20
2021 Q1	$5.36M	Sell	65,000 -10,000	-13%	-$958K	1%	21
2020 Q4	$6.82M	Sell	75,000 -25,000	-25%	-$1.55M	1.31%	20
2020 Q3	$4M	Hold	100,000	–	–	0.83%	24
2020 Q2	$3.43M	Buy	100,000 +50,000	+100%	+$1.49M	0.75%	24
2020 Q1	$1.11M	Hold	50,000	–	–	0.26%	34
2019 Q4	$978K	Buy	+50,000	New	+$794K	0.19%	37

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bruce & Co's FATE Position: Q2 2026 in Review

Bruce & Co increased its Fate Therapeutics (FATE) stake by 25% in Q2 2026, buying an estimated $370K and bringing the position to 989,188 shares worth $2.67M. The position accounts for 0.72% of the portfolio, ranked #28.

Bruce & Co first reported a position in FATE in Q4 2019 and has held it in 27 quarters since. The position peaked at $6.82M in Q4 2020. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

Bruce & Co held 989,188 shares of Fate Therapeutics worth $2.67M as of Q2 2026.
Bruce & Co bought 200,000 Fate Therapeutics shares in Q2 2026, an estimated $370K.
Fate Therapeutics made up 0.72% of Bruce & Co's portfolio in Q2 2026, its #28 holding.
Bruce & Co first reported a position in Fate Therapeutics in Q4 2019 and has held it in 27 quarters since.
Bruce & Co's Fate Therapeutics position peaked at $6.82M in Q4 2020.
156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Bruce & Co's 13F filing for Q2 2026, filed 14 Aug 2026.